What Is Cagrilintide?

Amylin is a 37-amino acid peptide hormone co-secreted with insulin from pancreatic beta cells in response to food intake. It acts on the area postrema and other brainstem regions to promote satiety, slow gastric emptying, and suppress post-meal glucagon secretion. However, native amylin has an extremely short half-life and tends to aggregate, making it impractical for therapeutic use.

Cagrilintide solves these problems through strategic amino acid substitutions and acylation with a C18 fatty acid chain, enabling albumin binding that extends its half-life to approximately one week. This allows convenient once-weekly dosing while maintaining potent amylin receptor agonism. Novo Nordisk is developing Cagrilintide both as a standalone agent and in combination with Semaglutide 2.4 mg (branded as CagriSema), which targets two distinct appetite pathways simultaneously.

Cagrilintide modulates appetite and metabolism through the amylin receptor system:

• Area postrema activation — Cagrilintide binds to amylin receptors (calcitonin receptor/RAMP complexes) in the area postrema, a circumventricular organ involved in appetite suppression and nausea signaling.
• Hypothalamic signaling — Downstream signaling reduces activity in hunger-promoting neurons and enhances satiety pathways in the hypothalamus, complementing but distinct from GLP-1 signaling.
• Gastric emptying delay — Like GLP-1 agonists, Cagrilintide slows gastric emptying, prolonging post-meal fullness and reducing total caloric intake.
• Glucagon suppression — Amylin signaling suppresses inappropriate post-meal glucagon release, improving glycemic control.
• Complementary to GLP-1 — Amylin and GLP-1 act on overlapping but distinct neuronal populations in the brain, creating additive appetite suppression when combined.

Clinical trial data for Cagrilintide — both standalone and in combination — has been encouraging:

• Standalone weight loss — Phase II trials of Cagrilintide alone (4.5 mg weekly) produced approximately 10.8% weight loss over 26 weeks, significant for a single-mechanism agent.
• CagriSema combination — When combined with Semaglutide 2.4 mg, early Phase III data shows approximately 22–25% weight loss, approaching bariatric surgery outcomes without surgical intervention.
• Additive appetite suppression — The combination of amylin and GLP-1 pathways produces greater satiety than either agent alone, with distinct mechanisms reducing the likelihood of neuronal adaptation.
• Glycemic improvement — Studies in type 2 diabetes populations show meaningful HbA1c reductions alongside weight loss.
• Potential durability — The dual-pathway approach may reduce the weight regain that sometimes occurs with single-agent GLP-1 therapy, though long-term data is still emerging.

Cagrilintide is administered via once-weekly subcutaneous injection with dose titration:

• Starting dose — Clinical trials initiated at 0.25 mg weekly, titrating over several weeks to the target dose.
• Target dose (standalone) — 2.4–4.5 mg once weekly, depending on tolerability and protocol goals.
• CagriSema dosing — The combination product uses Cagrilintide 2.4 mg + Semaglutide 2.4 mg in a single weekly injection.
• Titration schedule — Gradual dose escalation over 16–20 weeks is used to minimize gastrointestinal side effects.
• Injection sites — Abdomen, thigh, or upper arm, rotated between doses.

The once-weekly dosing is enabled by Cagrilintide's fatty acid acylation, which promotes albumin binding and extends circulating half-life to approximately 7 days. Store refrigerated and protect from light.

Cagrilintide's side effect profile reflects its mechanism as an amylin pathway agonist:

• Nausea — The most common side effect, occurring predominantly during dose escalation and typically improving with continued use.
• Vomiting and diarrhea — Gastrointestinal effects consistent with both amylin and GLP-1 agonist classes.
• Decreased appetite — A therapeutic effect that is sometimes reported as an adverse event in clinical trials.
• Injection site reactions — Mild erythema, pruritus, or induration at injection sites.
• Constipation — Reported in some subjects, likely related to slowed gastric motility.

Serious adverse events in clinical trials have been rare. The combination with Semaglutide does not appear to significantly worsen the GI side effect profile compared to Semaglutide alone, suggesting the two pathways may have complementary rather than additive tolerability issues.

Cagrilintide is an investigational drug currently in Phase III clinical trials. It is not approved by the FDA or any regulatory agency. Research peptide versions are sold strictly for in vitro research purposes only. This article is for informational and educational purposes and does not constitute medical advice.

As an investigational compound, Cagrilintide is available exclusively through research peptide channels:

• Synthesis complexity — Cagrilintide's acylated structure requires advanced peptide synthesis capabilities. Source only from established vendors.
• Purity verification — Insist on COAs with HPLC purity ≥98% and mass spectrometry confirming molecular identity.
• Proper storage — The acylated structure requires careful handling; ensure the vendor ships with appropriate cold chain protocols.

Ascension Peptides is our recommended vendor for research-grade Cagrilintide. They offer 99%+ purity verified by independent labs, comprehensive batch-specific COAs, and US-based cold chain shipping with 2–3 day delivery. Their experience with complex acylated peptides ensures you receive a reliable product for your research needs.